Imatinib Mesylate in Cutaneous Melanoma Pedro Redondo, Pedro Lloret, Enrique J. Andreu, Susana Inoges  Journal of Investigative Dermatology  Volume 123, Issue 6, Pages 1208-1209 (December 2004) DOI: 10.1111/j.0022-202X.2004.23496.x Copyright © 2004 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Effect of Gleevec on the growth of B16F10 melanoma cells in vivo. Although the differences are evident, there was no significant statistical difference in the growth of B16F10 melanoma cells in either the mice treated with Gleevec (n=11) or the control (n=6) groups at any point measured (p=0.116). This was probably due to the size of the groups. We used a nonparametric statistic test (Mann–Whitney test). The level of significance was set at p<0.05. Journal of Investigative Dermatology 2004 123, 1208-1209DOI: (10.1111/j.0022-202X.2004.23496.x) Copyright © 2004 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Imatinib mesylate treatment blocks proliferation of B16F10 melanoma cells. Cells were seeded at 100 × 103 cells per dish (3 cm diameter) 24 h before imatinib treatment (Novartis). (A) B16F10 melanoma cells were treated with 15 μM imatinib and maintained in culture for 24 h. Cells were harvested with trypsin and viable cell number was determined by trypan blue exclusion test. The results represent the mean and SEM of three independent experiments. (B) B16F10 melanoma cells were incubated with 15 μM imatinib or vehicle (control) for 24 h and then the cell cycle profile was analyzed by flow cytometry. The numbers represent the percentage of cells in S-G2/M as analyzed using the CellQuest software (BD Biosciences Franklin Lakes, New Jersey). Journal of Investigative Dermatology 2004 123, 1208-1209DOI: (10.1111/j.0022-202X.2004.23496.x) Copyright © 2004 The Society for Investigative Dermatology, Inc Terms and Conditions